Cosmos Health Inc. (COSM) AI Stock Analysis

Cosmos Health Inc. functions as a fully integrated pharmaceutical enterprise, specializing in branded and generic pharmaceuticals, nutraceuticals, over-the-counter medications, healthcare essentials, baby products, and medical devices. The company distributes products through multiple channels, including an ecommerce marketplace, wholesale pharmaceutical distributors, and independent retail pharmacies. It identifies, acquires, develops, and commercializes healthcare products to improve patient outcomes. Cosmos Health operates distribution centers in Greece and the United Kingdom, alongside operational warehousing facilities, to support logistics and global delivery from its headquarters in Chicago, Illinois.

Cosmos Health recorded a 5-year revenue compound annual growth rate of 3.3% from FY2020 to FY2025. Annual revenue grew 19.9% in FY2025 to $65.3M, up from $54.4M in FY2024 and $53.4M in FY2023. Gross margin was 12.1% in FY2025, compared to 7.9% in FY2024. Operating margin stood at -25.3% in FY2025, and net income was -$19.1M, representing an EPS of -$1.29. Over the trailing twelve months, revenue reached $73.7M with an operating margin of -15.4% and a profit margin of -33.1%. In the latest quarter ended June 30, 2026, quarterly revenue grew 28.8% year-over-year.

As of June 30, 2026, Cosmos Health held $1.8M in cash and short-term investments against total debt of $16.0M, resulting in net debt of $14.1M. The company reported a current ratio of 1.05 and a debt-to-equity ratio of 0.77, supported by shareholders' equity of $20.7M and total assets of $61.5M. In FY2025, operating cash flow was -$8.4M, leading to free cash flow of -$8.5M after capital expenditures of $55,675. Additionally, the company's share count increased 249.3% over five years.

Cosmos Health holds a market capitalization of $33.3M and an enterprise value of $55.3M. The stock trades at a price-to-sales ratio of 0.5x, well below the 4.1x median of its US-listed Healthcare peers. Its forward price-to-earnings ratio is 5.8x compared to the peer median of 17.3x, and enterprise value-to-revenue is 0.8x. Over the past year, the stock dropped 69.6%, while the S&P 500 returned 16.8%. Over a five-year period, the stock declined 99.7% compared to an 83.0% gain for the benchmark.

One analyst covers Cosmos Health with a mean price target of $4.50, representing a 1258.3% premium over the last close of $0.33. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.22 on revenue of $80.8M. For the next fiscal year, expectations are an EPS of $0.07 on revenue of $128.0M, reflecting 58.4% revenue growth. The company posted 0 EPS beats over the last four quarters. Its next earnings release is scheduled for November 13, 2026.

This page is an AI-written research summary of Cosmos Health Inc. (COSM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: COSM income statement, COSM balance sheet, COSM key metrics, COSM analyst forecast, COSM chart. See the COSM stock overview for the latest quote and news.